MedTrace Logo

Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

NCT03342690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1165

Last updated 2023-07-11

Study results available
· View outcomes & findings →

Summary

Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical Practice

Conditions

Interventions

DRUG

Eplerenone

In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily. Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-05
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03342690 on ClinicalTrials.gov